Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) saw a significant growth in short interest in August. As of August 14th, there was short interest totaling 4,359 shares, a growth of 184.7% from the July 30th total of 1,531 shares. Based on an average daily volume of 7,971 shares, the days-to-cover ratio is currently 0.5 days.
Defence Therapeutics Trading Down 2.0%
Shares of Defence Therapeutics stock opened at $0.37 on Friday. Defence Therapeutics has a 12-month low of $0.25 and a 12-month high of $0.78. The stock has a fifty day simple moving average of $0.32 and a 200 day simple moving average of $0.38.
Defence Therapeutics Company Profile
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Featured Stories
- Five stocks we like better than Defence Therapeutics
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
